TYPE 1 DIABETES GENETICS CONSORTIUM

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Type 1 Diabetes Genetics Consortium (T1DGC) will organize international efforts to identify genes that determine an individual's risk for type 1 diabetes. The scientific objectives of the Type 1 Diabetes Genetics Consortium are: 1. To ascertain, study and establish a renewable source of DNA on 3000 "affected sib-pair" (ASP) families with at least two type 1 diabetic siblings, their parents, and +/- up to two non-diabetic siblings for studies to map genes that may be associated with type 1 diabetes; 2. To create a database for the scientific community that would facilitate the search for type 1 diabetes susceptibility genes; 3. To provide a centralized DNA repository to allow targeted studies of genetic structure and function for type 1 diabetes; 4. To evaluate opportunities to extend the results of research to develop methods of risk prediction, prevention and therapy in the area of type 1 diabetes. To meet these objectives, the T1DGC will collect information and blood samples from sib-pair and trio families located in five study-defined geographic areas worldwide: Asia-Pacific, Europe, Latin America, North America, and the United Kingdom. The ultimate goal of this study is to provide the clinical and genetic resources to achieve the necessary sample size and sample availability for gene identification. The Consortium will establish a mechanism to ensure that scientists will work together toward a better understanding of the genetic factors that underlies risk for type 1 diabetes. The Consortium will gain a better understanding of disease mechanisms, with a purpose of altering these mechanisms and pathways in individuals at risk of type 1 diabetes.